Co-founder and CEO, Cincera Therapeutics
| Role | Organisation | Sources |
|---|---|---|
| Founder | Ankere Therapeutics | Brandon Capital portfolio, Brandon BioCatalyst portfolio |
| Co-founder and CEO | Cincera Therapeutics | Brandon Capital portfolio, Brandon BioCatalyst portfolio |
Stories naming Associate Professor Bernard Flynn. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Biotech startup Ankere Therapeutics launches with a $10 million seed round co-led by IP Group and Brandon Capital to develop inflammatory lung disease therapies, building on research from Monash and UniSA scientists.
Also Brandon Capital portfolio·Startup Daily·@AuManufacturing
Cincera Therapeutics has received a million-dollar Biomedical Translation Bridge grant to advance its Des-1 inhibitor drug for obesity-related metabolic diseases. The Monash and UniSA spin-out previously secured venture funding from the Medical Research Commercialisation Fund.